Therapeutic targeting of metabolic dysfunction by amino acid restriction and alternate day fasting in renal cell carcinoma models.

Sabrina Orsi,Chris Rupert,Musea Chang,Sean Colligan,Abbas Jawadwala,Ilaria Delle Fontane,Filomena De Nigris,Roberto Pili
DOI: https://doi.org/10.1200/jco.2024.42.4_suppl.469
IF: 45.3
2024-02-01
Journal of Clinical Oncology
Abstract:469 Background: The use of immunotherapies and targeted drugs has significantly improved the clinical outcome of kidney cancer patients. However, the inevitable long-term toxicities and development of drug resistance remain a critical challenge for advanced clear cell and non-clear cell renal cell carcinoma (RCC) patients thus highlighting the need for novel therapeutic strategies. Large-scale metabolomic data have associated metabolic alterations with the pathogenesis and progression of RCC. As diet has been reported to potentially modulate tumor metabolism, dietary interventions represent an innovative strategy to treat metabolically dysregulated tumors. However, the biological basis of the success of dietary interventions is unknown, representing a critical roadblock in the use of dietary restrictions in patients. In this study, we investigated the role of amino acid (AA) restriction and alternate day fasting in metabolic and energy dynamics in preclinical models of clear cell and translocation RCC with the overall goal of expanding the understanding of metabolism’s role in tumor progression and response to therapies. Methods: Seahorse, immunofluorescence, metabolomics, transcriptomics, genetic silencing, and pharmacological inhibition were utilized to assess the mechanisms underlying nutrient utilization and metabolic dysfunction in RCC. Patient-derived organoids and murine xenograft models were used to demonstrate the impact of dietary interventions and targeted therapies Results: Our data suggests that oxidative-phosphorylation is the main source of tumor-derived ATP in a subset of ccRCC cells but in all the tRCC cells assessed. AA restriction was associated with decreased oxidative phosphorylation in RCC models with baseline elevated mitochondrial function. Similarly, RCC models with a more glycolytic phenotype had decreased glycolytic function and reduced tumor burden in response to fasting conditions. The results from combining dietary interventions and targeted therapies are ongoing and will be presented. Conclusions: Our data suggests that oxidative-phosphorylation is the main source of tumor-derived ATP in a subset of ccRCC cells but in all the tRCC cells assessed. AA restriction was associated with decreased oxidative phosphorylation in RCC models with baseline elevated mitochondrial function. Similarly, RCC models with a more glycolytic phenotype had decreased glycolytic function and reduced tumor burden in response to fasting conditions. The results from combining dietary interventions and targeted therapies are ongoing and will be presented.
oncology
What problem does this paper attempt to address?